Castle Biosciences (NASDAQ: CSTL) — Perfil da empresa, notícias e dados financeiros
Castle Biosciences develops diagnostic tests for cancers, focusing on skin cancer and precision oncology.
Castle Biosciences
Castle Biosciences (NASDAQ:CSTL) specializes in developing and commercializing diagnostic and prognostic tests for cancers. They are devoted to transforming disease management through innovative molecular diagnostics that guide patient care. Their portfolio focuses chiefly on skin cancer, including melanoma, where they've made significant strides. Castle Biosciences aims to expand its impact by advancing the understanding of cancers at the genetic level, thus improving treatment decisions and outcomes for patients. Their objective is to lead in the realm of precision oncology, making personalized medicine more accessible and effective for cancer patients worldwide.
Resumo
Operações
Produtos e/ou serviços de Castle Biosciences
- DecisionDx-Melanoma, a diagnostic test predicting the risk of melanoma cancer spreading.
- DecisionDx-UM, a test to determine the risk of metastasis for uveal melanoma patients.
- DecisionDx-SCC, a genomic test for cutaneous squamous cell carcinoma prognosis.
- myPath Melanoma, a diagnostic tool distinguishing between benign moles and melanoma.
- DiffDx-Melanoma, aiding in the difficult diagnosis of melanoma versus benign skin lesions.
- TissueCypher, a Barrett's Esophagus test predicting progression to esophageal disease.
equipe executiva do Castle Biosciences
- Derek J. MaetzoldFounder, CEO, President & Director
- Frank StokesCFO & Treasurer
- Kristen M. OelschlagerChief Operating Officer
- Tobin W. JuvenalChief Commercial Officer
- Camilla ZuckeroVice President of Investor Relations & Corporate Affairs
- Kevin DomanSenior Vice President of Sales
- Jay BraxtonSenior Vice President of Marketing
- Keli GreenbergVice President of Human Resources
- Matthew GoldbergSenior Vice President of Medical
- Trisha PoteetSenior VP of Clinical Services & Manufacturing Operations
Principais indicadores financeiros
Resultados divulgados pela Castle Biosciences, em USD.
- Cap. de mercado
- 1,1 bi
- Receita (TTM)
- 357,3 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.7
- Dividend yield
- —
- Margem de lucro
- -5.4%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 344,2 mi | -42,8 mi | -24,2 mi | |
| 332,1 mi | 8,7 mi | 18,2 mi | |
| 219,8 mi | -68 mi | -57,5 mi | |
| 137 mi | -72,9 mi | -67,1 mi |